Status: Recruiting
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
Double-blind, randomised, placebo-controlled phase II / III trial evaluating efficacy and safety of two different doses (2 g/d or 3 g/d) of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to placebo in patients with ulcerative colitis (UC). The intended therapeutic use of CICR-NAM is to improve intestinal inflammation in adults with UC by topically increasing nicotinamide supply in the ileocolonic region and thus favourably influencing the composition of intestinal microbiota
Participants needed: 459
Trial details
Phase: Phase 2, Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: University Hospital Schleswig-HolsteinUpdated: Jun 11, 2026Locations: 26
Eligibility criteria
Male and female patients with UC and 18 to 80 years of age (at the time of signi... [+10]
Diagnosis of CD, microscopic colitis, ischaemic colitis, radiation colitis or in... [+27]